Key facts
- Notable investors include Nexus NeuroTech Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Lotus Neuro
- ·The full record, as it builds
Funding rounds
No funding rounds for Lotus Neuro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lotus Neuro
Developer of brain-targeted therapeutic technology designed to advance precision-focused ultrasound-enabled combination therapies for neurological diseases. The company focuses on combining low-frequency focused ultrasound with therapeutic agents to enable targeted treatment within specific regions of the brain, and its approach integrates patient-specific anatomy and disease biology, enabling clients to target neurological diseases with the help of localized brain therapy using focused ultrasound combined with therapeutic agents.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Website
- lotusneuro.com/
- Ownership
- Privately Held (backing)
Lotus Neuro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lotus Neuro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lotus Neuro in its N-PORT filings yet. We sweep new filings monthly.